Immune checkpoints such as TIGIT and CTLA4 were denser in low eIF3a group, indicating that eIF3a may not only provide therapeutic target for DLBCL patients but also act as potential predictors of immunotherapy responses. Here, TIGIT is linked to diffuse large B-cell lymphoma.